Abstract
A practical booster vaccine is urgently needed to control the coronavirus disease (COVID-19) pandemic. We have previously reported the safety and immunogenicity of a fractional intradermal booster, using the BNT162b2 mRNA vaccine in healthy volunteers who had completed two doses of inactivated SARS-CoV-2 vaccine. In this study, an intramuscular booster at full dosage was used as a control, and a half-dose vaccination was included for reciprocal comparison. Detailed T-cell studies are essential to understand cellular responses to vaccination. T-cell immunity was examined using S1 peptide restimulation and flow cytometry. The fractional dose (1:5) of the BNT162b2 mRNA vaccine enhanced antigen-specific effector T-cells, but the responses were less remarkable compared to the intramuscular booster at full dosage. However, the intradermal regimen was not inferior to the intramuscular booster a month after boosting. An intradermal booster using only one-fifth of the standard dosage could provide comparable T-cell responses with the fractional intramuscular booster. This work confirms the efficacy of intradermal and fractional vaccination in terms of T-cell immunogenicity in previously immunised populations.
Funder
National Vaccine Institute
Faculty of Medicine, Prince of Songkla University
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference32 articles.
1. Coronavirus Disease (COVID-19) Pandemic
https://www.who.int/europe/emergencies/situations/covid-19
2. Timeline: WHO’s COVID-19 Response
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#event-19
3. WHO Coronavirus (COVID-19) Dashboard
https://covid19.who.int/?mapFilter=cases
4. Local measures enable COVID-19 containment with fewer restrictions due to cooperative effects
5. Global impacts of pre- and post-COVID-19 pandemic: Focus on socio-economic consequences
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献